A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction
Status:
Completed
Trial end date:
2018-05-16
Target enrollment:
Participant gender:
Summary
The objective of the study is to find the optimal dose of once daily oral neladenoson
bialanate (BAY 1067197) when given in addition to standard therapy for heart failure with
reduced ejection fraction (HFrEF).